Abstract:Abstract Background Folic acid (FA) supplementation is associated with a lower risk of the neural tube and heart defects and is recommended for women of childbearing age. Although there are detailed recommendations, differences in the initiation time and duration of FA supplementation remain poorly studied. Methods A multicentre prospective study of 17,713 women was conducted. The incidence of congenital malformations in women taking a recommended dosage (e.g. 0.4 or 0.8 mg/day) of FA was compared with that in women without supplementation. The predicted probability of malformations by the initiation time and duration of FA use was estimated to determine optimal options. Results Periconceptional FA supplementation was associated with a lower and insignificant risk of congenital malformations (1.59% vs. 2.37%; odds ratio [OR] 0.69; 95% confidence interval [CI]: 0.44–1.08), heart defects (3.8 vs. 8.0 per 1000 infants; OR, 0.47; 0.21–1.02), and neural tube defects (7.0 vs. 11.5 per 10,000 infants; OR, 0.64; 0.08–5.15). FA use after pregnancy provided greater protection against total malformations. Statistically significant associations were found in women who initiated FA supplementation in the first month of gestation (OR, 0.55; 95% CI: 0.33–0.91) and in those who supplemented for 1 to 2 months (OR, 0.59; 95% CI: 0.36–0.98). Similar results were found for heart defects. The optimal initiation time was 1.5 (optimal range: 1.1 to 1.9) months before pregnancy and a duration of 4.0 (3.7 to 4.4) months was reasonable to achieve the lowest risk of congenital malformations. Heart defect prevention required an earlier initiation (2.2 vs. 1.1 months before pregnancy) and a longer duration (4.7 vs. 3.7 months) than the prevention of other malformations. Conclusions The timely initiation of FA supplementation for gestation was associated with a decreased risk of congenital malformations, which was mainly attributed to its protection against heart defects. The initiation of FA supplementation 1.5 months before conception with a duration of 4 months is the preferred option for congenital malformation prevention. Trial registration Chictr.org.cn identifier: ChiCTR-SOC-17010976.

The association between periconceptional folic acid supplementation and congenital heart defects: a case-control study in China.

Periconceptional Factors Affect the Risk of Neural Tube Defects in Offspring: a Hospital-Based Case-Control Study in China.

Maternal Periconceptional Folic Acid Supplementation and Risk for Fetal Congenital Heart Defects.

Maternal body mass index and the association between folic acid supplements and neural tube defects.

Effects of Folic Acid Supplementation During Different Pregnancy Periods and Relationship with the Other Primary Prevention Measures to Neural Tube Defects

A case -control study on the risk factors of congenital heart disease among perinatal infants

The Effects of Preconception Examinations on Neural Tube Defects and the Primary Preventive Measures: Case-Control Study

Association between congenital heart disease and folic acid supplementation during periconceptional period among women of childbearing age in Shaanxi

Folic acid supplementation and risk for congenital hydrocephalus in China

Preconception Folic Acid Supplementation for the Prevention of Birth Defects: a Prospective, Population-Based Cohort Study in Mainland China

Pre-conceptional Intake of Folic Acid Supplements is Inversely Associated with Risk of Preterm Birth and Small-for-gestational-age Birth: a Prospective Cohort Study

The association between periconceptional folic acid supplementation and the risk of preterm birth: a population-based retrospective cohort study of 200,000 women in China

Folic Acid Supplementation and Risk for Congenital Limb Reduction Defects in China

First-Trimester Maternal Folic Acid Supplementation Reduced Risks of Severe and Most Congenital Heart Diseases in Offspring: A Large Case-Control Study.

Periconceptional Folic Acid Supplementation and the Risk of Preterm Births in China: a Large Prospective Cohort Study.

Initiation and duration of folic acid supplementation in preventing congenital malformations

Periconceptional Use Of Folic Acid In Shanxi Province Of Northern China

A propensity-matched study of the association between optimal folic acid supplementation and birth defects in Shaanxi province, Northwestern China

Folic Acid Supplements and Perinatal Mortality in China

Periconceptional folic acid supplementation is a risk factor for childhood asthma: a case-control study

Periconceptional Folic Acid Use and Its Effects on Neural Tube Defects — Five Counties, Shanxi Province, China, 2010–2016